XIENCE V: SPIRIT WOMEN Sub-study

General Inclusion Criteria:

• Patient must be female.

• Patient must be at least 18 years of age.

• Patient is able to verbally confirm understanding of risks, benefits and treatmentalternatives and she or her legally authorized representative provides writteninformed consent prior to any study related procedure, as approved by the appropriateMedical Ethics Committee of the respective clinical site.

• Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,silent ischemia, positive functional study or a reversible change in theelectrocardiogram (ECG) consistent with ischemia).

• Patient must be an acceptable candidate for coronary artery bypass graft (CABG)surgery.

• Patient must agree to undergo all protocol-required follow-up examinations.

• Patients of childbearing potential must have had a negative pregnancy test within 7days before treatment, and must not be nursing at the time of treatment. Angiographic Inclusion Criteria:

• Patients' artery morphology and disease is suitable to be optimally treated with amaximum of 4 planned study stents.

• Target lesions must be de novo lesions (no prior stent implant, no priorbrachytherapy).

• Target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate.The diameter range will be expanded to 2.25 mm when the 2.25 mm stent is available.

• Target lesion greater than or equal to 28 mm in length by visual estimate.

General Exclusion Criteria:

• Patient has other medical illness (e.g., cancer or congestive heart failure) or knownhistory of substance abuse (alcohol, cocaine, heroin etc.) that may causenon-compliance with the clinical investigation plan, confound the data interpretationor is associated with a limited life expectancy (i.e., less than one year).

• Patient has a known hypersensitivity or contraindication to aspirin, either heparin orbivalirudin, both clopidogrel and ticlopidine, everolimus, cobalt, chromium, nickel,tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot beadequately pre-medicated.

• Participation in another device or drug study or has completed the follow-up phase ofanother study within the last 30 days.

• Patient who is judged to have a lesion that prevents complete inflation of anangioplasty balloon.

• Patient has had a previous stent implant, either Bare Metal Stent (BMS) or DrugEluting Stent (DES) within the target vessel(s)